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Abstract
The weighted average treatment effect (WATE) is a causal measure for
the comparison of interventions in a specific target population, which may
be different from the population where data are sampled from. For instance,
when the goal is to introduce a new treatment to a target population, the
question is what efficacy (or effectiveness) can be gained by switching pa-
tients from a standard of care (control) to this new treatment, for which the
average treatment effect for the control (ATC) estimand can be applied. In
this paper, we propose two estimators based on augmented inverse proba-
bility weighting to estimate the WATE for a well defined target population
(i.e., there exists a target function that describes the population of interest),
using observational data. The first proposed estimator is doubly robust if the
target function is known or can be correctly specified. The second proposed
estimator is doubly robust if the target function has a linear dependence on
the propensity score, which can be used to estimate the average treatment
effect for the treated (ATT) and ATC. We demonstrate the properties of the
proposed estimators through theoretical proof and simulation studies. We
also apply our proposed methods in a comparison of glucagon-like peptide-
1 receptor agonists therapy and insulin therapy among patients with type 2
diabetes, using the UK clinical practice research datalink data.
Keywords: Propensity score; Weighting; Confounding; Causal inference; Doubly
robust estimator
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1 Introduction
In causal inference, the average treatment effect (ATE) is a standard measure for
the comparison of interventions. It is defined on the entire population where data
are sampled from. In certain scenarios, the target population may be either a sub-
population or a population with different covariate distributions. Our motivating
example is an observational study to compare the effectiveness of glucagon-like
peptide-1 receptor agonists (GLP-1 RA) therapy (treatment) and insulin therapy
(control) for patients with type 2 diabetes (T2D). Due to the weight loss benefit
of GLP-1 RA therapy [1], physicians tend to prescribe it more often for patients
with higher body mass index (BMI) as their first-line injectable anti-diabetic treat-
ment. To address questions on the effectiveness of using GLP-1 RA therapy if we
switch first-line injectable insulin users to GLP-1 RA therapy, a useful estimand
is the ATE for the control (ATC). Generally, when the goal is to introduce a new
treatment to a target population, the question is what efficacy (or effectiveness) can
be gained by switching patients from a standard of care to this new treatment, in
which case, the ATC estimand should be considered. However, when the primary
interest is in the safety problems caused by a certain medication, the question is
about the difference in adverse events if patients who currently take the medica-
tion switch to a standard of care, in which case, the ATE for the treated (ATT)
estimand should be applied. Furthermore, there is the issue of external validity,
i.e., the generalizability of a random sample to a target population [2–4]. Due to
selection bias or other difficulties in collecting samples, the study population may
be different from the prespecified target population. Therefore, adjustments have
to be made for valid causal inference about the target population. Assuming suffi-
cient overlap in key features between the sampled data and the target population,
we can weight the samples according to the covariate distributions of the target
population in order to make valid causal inference, leading to the weighted ATE
(WATE) [5].
Various balancing weights have been proposed for the estimation of the WATE
in a prespecified target population, in addition to the ATT and ATC. A useful ex-
ample is the overlap weights, with a patient’s probability of being sampled propor-
tional to the product of the treatment probability and the control probability [6,7].
Patients who, based on their characteristics, are equally likely to be administered
treatment or control in standard practice are given a larger representation in the
study. The estimand by overlap weighting is called the ATE for the overlap popu-
lation (ATO), which, of all WATEs, achieves the smallest asymptotic variance as
well as exact balance of covariates between two treatment groups [7, 8].
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In observational studies, certain assumptions are required for the identification
of the WATE. In order to make internally valid causal interpretation, one has to
adjust for confounding, which results from potential covariate imbalance between
the two treatment arms. Commonly used methods to adjust for covariate imbal-
ance include regression, matching (e.g., [9] and [10]) and weighting (e.g., [11]
and [5]), with the last two relying on the propensity score, defined as the condi-
tional probability of receiving treatment given covariates. Due to concerns about
model misspecification in those methods, recently there has been substantive in-
terest in doubly robust estimators, which involve models for both the propen-
sity score and the conditional mean of the outcome, and remain consistent if ei-
ther model is correctly specified. The original doubly robust estimator is con-
structed by augmented inverse probability weighting (AIPW) in the missing data
setting [12]. Later, a number of doubly robust estimators have been proposed in
both missing data and causal inference settings (e.g., [13], [14], [15] and [16]).
However, the majority of these doubly robust estimators in the causal inference
setting are for the ATE. To our knowledge, very few studies have worked on dou-
bly robust estimators for the WATE (e.g., Kaiser [17] on the ATT for nonnegative
outcome).
In this paper, we propose two estimators based on AIPW for the WATE that
enjoy double robustness (i.e., consistent if either the propensity score or the con-
ditional mean model is correctly specified). Given a known or correctly specified
function that indicates the target population, the first proposed estimator is dou-
bly robust. It is also more efficient than the estimator based on inverse probability
weighting (IPW) if both the propensity score and the conditional mean models are
correctly specified. When the function for the target population is subject to mis-
specification, for example, if it depends on the propensity score, the first estimator
is no longer doubly robust. However, in the case of the target function linearly de-
pendent on the propensity score, the second proposed estimator is doubly robust,
which can be used to estimate the ATT and ATC.
The remainder of the paper is organized as follows. In Section 2, we intro-
duce notation and assumptions to identify the WATE, and propose robust estima-
tors. We then demonstrate in Section 3 the properties of the proposed estimators
through simulation studies. In Section 4, we apply the proposed estimators to the
motivating example to compare the GLP-1 RA therapy and insulin therapy for
T2D patients, using the UK clinical practice research datalink (CPRD) data. Fi-
nally, we summarize our main contributions and discuss about future development
in Section 5.
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2 Weighted average treatment effect (WATE)
2.1 Definition and identifiability
Consider a random sample of size n from a population of interest. Let A denote
the treatment indicator for each subject, with A ∈ A = {0, 1} (e.g., insulin and
GLP-1 RA). Let X = (X1, . . . , Xp)
⊤ be a p × 1 vector of subject characteristics
recorded prior to assigning treatment, and Y be the observed outcome of inter-
est (e.g., blood glucose). The observed data are {(Yi, Ai,X
⊤
i )}
n
i=1, assumed to
be independent and identically distributed across i. For brevity, we suppress the
subject index i in the following text when no confusion exists.
Under the counterfactual framework for causal inference [18], we denote Y (1)
as the counterfactual outcome that would be observed for a subject if, possibly
contrary to fact, treatment A = 1 were assigned and Y (0) as the counterfactual
outcome if treatment A = 0 were assigned. Then the ATE is
τ = E{Y (1)− Y (0)}.
Suppose the marginal density of X, denoted as f(X), exists. Instead of focus-
ing on the entire population as in τ , one may be interested in a specific target
population, which can be represented by f(X)h(X)/E{h(X)}, where h(·) is a
prespecified function of X that determines the distribution of the target popula-
tion. In other words, f(X)h(X)/E{h(X)} is the marginal density of X in the
target population, and the function h(X) is to ensure external validity. Then the
WATE can be expressed as
τh =
E [h(X){Y (1)− Y (0)}]
E{h(X)}
. (1)
The ATE is a special case of τh with h(X) = 1.
Note that τh is defined by counterfactual effects; for a given subject, Y (1) and
Y (0) cannot both be observed. To connect the counterfactual outcomes with the
observed data, we make the three standard assumptions [19, 20]:
1. Consistency: Y = AY (1) + (1 − A)Y (0), meaning that the observed out-
come is the same as the counterfactual outcome under the treatment a patient
is actually given, implying no interference between subjects.
2. Strong ignorability: A |= {Y (1), Y (0)}|X, meaning that the treatment as-
signment is independent of the counterfactual outcomes, conditional on pre-
treatment variables implying that there is no unmeasured confounding.
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3. Positivity: Pr{π(X) ∈ (0, 1)} = 1 with π(X) = Pr(A = 1|X).
π(X) is commonly referred to as the propensity score which is often unknown,
and thus it is customary to posit a model π(X, α), such as logistic regression, to
estimate it. We denote αˆ as a consistent estimator for α based on observed data,
using, for example, maximum likelihood estimation. Similarly, the conditional
meanmA(X) = E(Y |A,X) can be modeled bymA(X, β), and the function h(X)
for the target population can be modeled by h(X, γ). We denote βˆ and γˆ as
consistent estimators for β and γ, respectively, using observed data.
2.2 Estimation of the WATE with correctly specified h(X, γ)
In this section, we estimate the WATE given that the target function h(X, γ) is
correctly specified. This also includes the case where h(X) can be fully specified
without unknown parameters, for example, h(X) = I(Age > 50) with I(·) as
a binary indicator function. We derive three estimators of the WATE based on
outcome regression, IPW and AIPW.
First of all, it is easy to see that E{h(X)Y (A)} = E[E{h(X)Y (A)|X}] =
E{h(X)mA(X)}. Hence, an estimator of τh is
τˆRh =
∑
i h(Xi, γˆ){m1(Xi, βˆ)−m0(Xi, βˆ)}∑
i h(Xi, γˆ)
, (2)
where the superscript R represents outcome regression which can be parametric
or nonparametric.
Alternatively, we can estimate τh following the idea of IPW. Defining weights{
w1(X) =
h(X)
pi(X)
, for A = 1
w0(X) =
h(X)
1−pi(X)
, for A = 0,
(3)
we have
E{AY w1(X)} = E{Y (1)h(X)},
E{(1− A)Y w0(X)} = E{Y (0)h(X)},
and
E{Aw1(X)} = E{(1−A)w0(X)} = E{h(X)}.
Therefore, by equation (1), an IPW estimator of τh is
τˆ Ih =
∑
iAiYiw1(Xi, αˆ, γˆ)∑
iAiw1(Xi, αˆ, γˆ)
−
∑
i(1−Ai)Yiw0(Xi, αˆ, γˆ)∑
i(1− Ai)w0(Xi, αˆ, γˆ)
, (4)
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where wA(Xi, αˆ, γˆ) is a function of h(Xi, γˆ) and π(Xi, αˆ) as in (3). Equivalently,
we can estimate τh as
τˆ Ih =
∑
i h(Xi, γˆ)
{
AiYi
pi(Xi,αˆ)
− (1−Ai)Yi
1−pi(Xi,αˆ)
}
∑
i h(Xi, γˆ)
. (5)
τˆ Ih in (4) and (5) are both consistent but (4) uses normalized weights and is more
stable given a small sample size. We use form (4) in our simulations.
Following the idea of AIPW intended for improved efficiency and robustness,
when h(X, γ) is correctly specified, we further derive
E
{
AY h(X)
π(X, α)
−
A− π(X, α)
π(X, α)
m1(X, β)h(X)
}
= E {Y (1)h(X)}+ E
[
A− π(X, α)
π(X, α)
{Y (1)−m1(X, β)}h(X)
]
= E {Y (1)h(X)} ,
where the last equation holds if either the propensity score model π(X, α) or the
conditional mean modelm1(X, β) is correctly specified. Similarly, we derive
E
{
(1− A)Y h(X)
1− π(X, α)
+
A− π(X, α)
1− π(X, α)
m0(X, β)h(X)
}
= E {Y (0)h(X)}+ E
[
A− π(X, α)
1− π(X, α)
{m0(X, β)− Y (0)}h(X)
]
= E{Y (0)h(X)},
where the last equation holds if either the propensity score model π(X, α) or the
conditional mean modelm0(X, β) is correctly specified.
Therefore, when h(X, γ) is correctly specified, we propose an AIPW estima-
tor for τh, as
(6)
τˆAh =
1∑
i h(Xi, γˆ)
∑
i
h(Xi, γˆ)
[{
AiYi
π(Xi, αˆ)
−
Ai − π(Xi, αˆ)
π(Xi, αˆ)
m1(Xi, βˆ)
}
−
{
(1− Ai)Yi
1− π(Xi, αˆ)
+
Ai − π(Xi, αˆ)
1− π(Xi, αˆ)
m0(Xi, βˆ)
}]
.
Theorem 1. Given the assumptions of consistency, strong ignorability and posi-
tivity, and a correctly specified h(X, γ), τˆAh in (6) has the following properties:
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1. Double Robustness: τˆAh is a consistent estimator of the τh if either the
propensity score model π(X, α) or the conditional mean model mA(X, β)
is correctly specified.
2. Improved Efficiency: when π(X, α) is correctly specified, if mA(X, β) is
also correctly specified, τˆAh achieves better efficiency than τˆ
I
h .
The first property is obvious by the construction of τˆAh . To see the second
property, given correctly specified h(X, γ) and π(X, α), using the total variance
formula var(·) = E[var{·|X, Y (1), Y (0)}] + var[E{·|X, Y (1), Y (0)}], we have
var
[{
AY h(X)
pi(X)
− A−pi(X)
pi(X)
m1(X, β)h(X)
}
−
{
(1−A)Y h(X)
1−pi(X)
+ A−pi(X)
1−pi(X)
m0(X, β)h(X)
}]
equal to
E
[
π(X){1− π(X)}h2(X)
{
Y (1)−m1(X, β)
π(X)
+
Y (0)−m0(X, β)
1− π(X)
}
2
]
+ var[{Y (1)− Y (0)}h(X)].
It is easy to see that the above variance achieves minimal when the conditional
mean modelmA(X, β) is correctly specified. Since τˆ
I
h is a special case of τˆ
A
h with
mA(X, β) = 0, we have the second property.
Remark. With h(X) = π(X){1 − π(X)}, the weights w1(X) = 1 − π(X)
for A = 1 and w0(X) = π(X) for A = 0 are called overlap weights in [7], which
lead to τh with the smallest asymptotic variance among all WATEs if π(X, α) is
correctly specified [7,8]. By Theorem 1 Property 2, we could achieve the smallest
asymptotic variance by using τˆAh given correctly specified π(X, α) andmA(X, β).
Moreover, the overlap weights can balance the small-sample means of all covari-
ates involved in the propensity score model when the propensity scores are esti-
mated by maximum likelihood under a logistic model [7]. In addition, the overlap
weights are stable in the presence of extreme propensity scores.
2.3 Estimation of the WATE with correctly specified h(X, γ)
TheWATE τh defines a general class of estimands by using h functions for various
target populations. When h(X, γ) can be correctly specified, we have the doubly
robust estimator τˆAh for τh as shown in Section 2.2. In some scenarios, we know
the form of h(X) but could not guarantee the correct specification of h(X, γ).
For example, in an observational study, if h(X) is a function of π(X), h(X, γ) is
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subject to the misspecification of π(X, α). Then the results in Section 2.2 may
not hold.
Two important cases are the ATT and ATC. Given h(X) = π(X), τh is equal
to the ATT, i.e.,
τpi =
E [π(X){Y (1)− Y (0)}]
E{π(X)}
= E{Y (1)− Y (0)|A = 1}.
Given h(X) = 1− π(X), τh is equal to the ATC, i.e.,
τ1−pi =
E [{1− π(X)}{Y (1)− Y (0)}]
E{1− π(X)}
= E{Y (1)− Y (0)|A = 0}.
With h(X) depending on π(X), the estimator τˆAh for the ATT or the ATC is no
longer doubly robust since a misspecified propensity model may lead to a wrong
target population. However, it is straightforward to figure out the regression-based
and IPW estimators separately for both the ATT and the ATC. Specifically, for the
ATT, we have
τˆRpi =
∑
iAi{Yi −m0(Xi, βˆ)}∑
iAi
and τˆ Ipi =
∑
i{AiYi −
pi(Xi,αˆ)(1−Ai)
1−pi(Xi,αˆ)
Yi}∑
i π(Xi, αˆ)
.
For the ATC, we have
τˆR1−pi =
∑
i(1−Ai){m1(Xi, βˆ)− Yi}∑
i(1−Ai)
and τˆ I1−pi =
∑
i{
1−pi(Xi,αˆ)
pi(Xi,αˆ)
AiYi − (1− Ai)Yi}∑
i{1− π(Xi, αˆ)}
.
By combining the regression-based and IPW estimators, we find the following
doubly robust estimators for the ATT and the ATC.
Proposition 2. Given the assumptions of consistency, strong ignorability and pos-
itivity, τˆDBpi with the form
τˆDRpi =
∑
i
[
AiYi −
{
pi(Xi,αˆ)(1−Ai)
1−pi(Xi,αˆ)
Yi +
Ai−pi(Xi,αˆ)
1−pi(Xi,αˆ)
m0(Xi, βˆ)
}]
∑
iAi
(7)
is a consistent estimator of the ATT if either the propensity score model π(X, α)
or the conditional mean modelm0(X, β) is correctly specified, and τˆ
DB
1−pi with the
form
τˆDR1−pi =
∑
i
[{
1−pi(Xi,αˆ)
pi(Xi,αˆ)
AiYi −
Ai−pi(Xi,αˆ)
pi(Xi,αˆ)
m1(Xi, βˆ)
}
− (1− Ai)Yi
]
∑
i(1−Ai)
(8)
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is a consistent estimator of the ATC if either the propensity score model π(X, α)
or the conditional mean modelm1(X, β) is correctly specified.
Moreover, we consider a general form h(X) = a + bπ(X), where a and b are
known constants with a2 + b2 > 0. Then the ATT and the ATC are special cases
with a = 0, b = 1 and a = 1, b = −1. We have the following theorem for a
doubly robust estimator of τh. The proof is in the Appendix, which also implies
Proposition 2.
Theorem 3. Given the assumptions of consistency, strong ignorability and posi-
tivity, and h(X) = a+ bπ(X), τˆDRh with the form
τˆDRh =
1∑
i(a+ bAi)
∑
i
(
(a + bAi){m1(Xi, βˆ)−m0(Xi, βˆ)}
+ {a+ bπ(Xi, αˆ)}
[
Ai
π(Xi, αˆ)
{Yi −m1(Xi, βˆ)}
−
1−Ai
1− π(Xi, αˆ)
{Yi −m0(Xi, βˆ)}
])
is a consistent estimator of τh if either the propensity score model π(X, α) or the
conditional mean modelmA(X, β) is correctly specified.
For the ATO, denoting the probability limit of the propensity score under the
misspecified model as π∗(X) and assuming a correctly specified conditional mean
model, the ATO estimator is consistent for
E [h∗(X){Y (1)− Y (0)}]
E{h∗(X)}
, (9)
with h∗(X) = π∗(X){1−π∗(X)}. In other words, it retains a causal interpretation
with a misspecified propensity score model and a correctly specified conditional
mean model. Given an intercept-only model for the propensity score, equivalent
to using sample proportions, the estimand (9) is reduced to the ATE. By using a
model that explains only part of the total variance in the treatment assignment,
we expect the estimand (9) to yield an estimate somewhere between the ATE and
ATO estimates when these two are estimated under correct models for both π and
m. Therefore, as a trade-off in certain scenarios, one may favor the estimand (9)
due to its stableness against extreme weights and asymptotic efficiency.
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3 Simulation studies
We conduct simulation studies to evaluate the performance of the proposed es-
timators under four possible combinations of correctly and incorrectly specified
propensity score model and conditional mean model. We consider estimands of
the ATE, ATT, ATC and ATO, with τˆAh for the ATE and ATO and τˆ
DR
h for the ATT
and ATC. For comparison, we also apply the corresponding regression-based and
IPW estimators for each estimand, with the criteria being average bias and root
mean square error (RMSE) over 1000 Monte Carlo replications. We consider
sample sizes of 200 and 1000.
We simulate five covariatesX = (X1, . . . , X5)
⊤ following N(0, I5) where I5
is a 5× 5 identity matrix. Treatment A is generated from Binomial{π(X)} with
logit{π(X)} = 0.5 +X1 − 0.5X
2
2 + 0.5X3X5 and logit(π) = log{π/(1 − π)}.
Outcome Y is generated from two difference models:
1. Y = 1 +X22 +X3 + A exp(X1 + 0.5X3X5) + ǫ,
2. Y = 1 +X22 +X3 + A(X1 + 0.5X3X5) + ǫ,
with ǫ ∼ N(0, 1). Outcome model 1 indicates an overall advantage of treatment
A = 1 over treatment A = 0 while outcome model 2 indicates no overall dif-
ference. The true values for the ATE, ATT, ATC and ATO are 1.90, 2.75, 1.04
and 1.50, respectively, under outcome model 1, and 0, 0.46, −0.46 and 0 under
outcome model 2. Note that the ATE and ATO are different under outcome model
1 but the same under outcome model 2, due to the fact that Y (1) under outcome
model 1 is skewed to have more large values while Y (1) under outcome model 1
and Y (0) under both models are more symmetric.
The misspecified outcome regression model is m
′
(X) = γ0 +
∑5
k=1 γkXk +
A(η0+
∑5
j=1 ηjXj), which leads toR
2 around 0.2 for outcomemodel 1 and 0.3 for
outcome model 2 (The correctly specified model has R2 around 0.9 for outcome
model 1 and 0.8 for outcome model 2). The misspecified propensity model is
logit{π
′
(X)} = ζ0 +
∑5
k=1 ζkXk, leading to a correlation around 0.75 between
the linear predictors logit{πˆ
′
(X)} and the truth logit{π(X)}.
Table 1 summarizes the performances of all estimators considered under out-
come model 1. When both propensity score and conditional mean models are
correctly specified, all estimators have minimal bias and RMSE, with τˆRh and the
proposed estimators (τˆAh for the ATE and ATO and τˆ
DR
h for the ATT and ATC)
both more efficient than τˆ Ih . When only π(X, α) is correctly specified, the pro-
posed estimators are consistent despite moderate biases for the ATE and ATC
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under sample size 200. When onlymA(X, β) is correctly specified, the proposed
estimators yield unbiased estimates for the ATE, ATT and ATC with RMSE simi-
lar to τˆRh . However, for the ATO, there is moderate bias because its target function
h(X, γ) = π(X, α){1−π(X, α)} is misspecified. Nonetheless, we do observe the
improved efficiency of the ATO over the ATE. With at least one model correctly
specified, our proposed estimators have either similar or better performance com-
pared to τˆ Ih . In addition, increasing the sample size reduces the bias and RMSE
in general, with τˆ Ih and the proposed estimators with only π(X, α) correct having
the most improvement.
Results under outcome model 2 are presented in Table 2. Similar to Table
1, Table 2 corroborates the double robustness of the proposed estimators for the
ATE, ATT and ATC.When π(X, α) is correctly specified, our proposed estimators
with a misspecified but informative mA(X, β) have similar RMSE as τˆ
I
h . When
mA(X, β) is correctly specified, our proposed estimators have similar RMSE as
τˆRh , which is better than τˆ
I
h , regardless of the specification of π(X, α). The major
difference between Table 1 and Table 2 lies in the ATO estimates given misspec-
ified π(X, α) and correctly specified mA(X, β). τˆ
A
h is not doubly robust for the
ATO since its target function h(X, γ) depends on π(X, α). As mentioned in Sec-
tion 2.3, when the misspecified π(X, α) explains partially the variation, we expect
the ATO estimate falls somewhere between the ATE and ATO estimates given cor-
rectly specified models for both π and m. This likely explains why we observe
positive bias when the ATE is greater than the ATO under outcome model 1, and a
consistent estimate when the ATE and ATO are the same under outcome model 2.
Under both outcome models, τˆAh for the ATO performs similarly to, if not better
than, τˆ Ih , with a correctly specified mA(X, β) leading to improved performance
of τˆAh over τˆ
I
h given the same π(X, α). In summary, despite not having double
robustness for the ATO, τˆAh shows to be a better choice than τˆ
I
h .
4 Application
In this section we apply our proposed estimators to the CPRD data featuring pa-
tients with T2D from the UK. We include patients of age ≥ 21 who were active
(i.e., registered at a CPRD practice) during the study period from January 1, 2011
to December 31, 2014. Treatment of interest is the GLP-1 RA therapy, which is a
relatively new first-line injectable anti-diabetic treatment for T2D patients, com-
pared to the standard of care of insulin therapy. GLP-1 RA therapy usually works
as a once daily or weekly injectable, as opposed to multiple daily injections for
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common insulin therapy, and has been shown with lower risk of hypoglycemia
and better weight control [1, 21]. Outcome is the reduction of hemoglobin A1c
(HbA1c, %) six months after initiation of the treatment.
We have 436 patients on insulin and 192 on GLP-1 RA. Patients on insulin
were overall older than patients on GLP-1 RA (mean: 61.7 years vs. 54.5 years)
with higher baseline HbA1c (mean: 10.4% vs. 9.5%). Another major difference
was that patients on GLP-1 RA had much higher BMI (mean: 39.1 vs. 29.2).
This is consistent with previous studies as physicians would more likely prescribe
GLP-1 RA for patients with weight issues due to its significantly better weight
control [1,21]. We aim to investigate whether the GLP-1 RA therapy comes at the
cost of worse glycemic control than insulin therapy for those target patients by ap-
plying the ATT estimand. Another goal is to gain insight into whether switching
current insulin users to GLP-1 RA in order to reduce treatment burden is a reason-
able treatment recommendation, for which we will apply the ATC estimand. Other
baseline covariates include gender, smoking status, lipid levels, comorbidities and
use of oral anti-diabetic medications. Missing data is imputed using R package
mice. We fit a logistic regression model with main effects of all baseline covari-
ates for the propensity scores and a linear regression model with main effects of
treatment and baseline covariates as well as the interaction terms of treatment by
baseline covariates for the conditional means. To avoid extreme weights, we trun-
cate the estimated propensity scores by the 5th and 95th percentiles.
The WATE estimates with bootstrap standard errors (SEs) are shown in Ta-
ble 3. Due to covariate imbalance in the two treatment groups, we observe very
different results before and after covariate adjustment. Without weighting, the in-
sulin group has significantly better HbA1c reduction than the GLP-1 group, with
an estimated mean difference of 1.06%. In contrast, the estimates for all esti-
mands are much smaller after adjustment for covariate imbalance, yielding no
statistical significance. Our proposed estimators result in smaller estimates than
τˆRh and τˆ
I
h for all estimands. The ATE estimate of 0.13% means that patients on
insulin have on average 0.13% more HbA1c reduction than those on GLP-1 RA.
Existing meta-analyses have discovered either no significant difference between
the two treatment groups [21], or slightly higher HbA1c reduction in the insulin
group [1]. An estimate of 0.14% reported by Wang et al. [1] is very close to the
ATE estimate by our proposed estimator τˆAh , although our SE is much larger likely
due to a smaller sample size. In particular, the ATT estimate is the closest to zero,
meaning that these younger and more overweight patients with lower baseline
HbA1c would have similar glycemic control with either treatment. Therefore, our
study supports the prescription of GLP-1 RA as opposed to insulin for these target
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patients so as to enjoy the better weight control and lower rate of hypoglycemia
without sacrificing the glycemic control [1, 21]. The nonsignificant ATC estimate
of 0.19% supports the idea of switching current insulin users to GLP-1 RA for
less frequent injection. As expected, the ATO estimates have smaller SEs than all
other estimands.
5 Discussion
We have proposed estimators for a general class of WATEs defined by the target
function h, which is flexible in estimating the ATE for a target population while
controlling for covariate imbalance in an observational study. By combining the
regression-based and IPW estimators, we have proposed new estimators for var-
ious WATEs. Given a correctly specified h(X, γ), the proposed estimator τˆAh is
doubly robust, meaning that it is consistent if either the propensity score model
π(X, α) or the conditional mean model mA(X, β) is correctly specified. It also
enjoys better efficiency than the IPW estimator τˆ Ih if both π(X, α) and mA(X, β)
are both correctly specified. Moreover, our simulation studies show that τˆAh has
either similar or better efficiency compared to τˆ Ih if at least one of the two models
is correctly specified, and it is also a better choice for the ATO even without dou-
ble robustness. When h(X, γ) is a linear function of π(X, α), which is subject to
model misspecification, we have proposed a doubly robust estimator τˆDRh , which
can be used to estimate the ATT and ATC, two common estimands in practice.
The proposed estimators can be further improved in several directions. First,
one can incorporate the idea by Han and Wang [22] to allow multiple models for
both the propensity score and the conditional mean so as to go beyond double ro-
bustness. Second, the propensity score estimation can be modified to improve the
empirical performance of propensity score weighting methods, for example, the
covariate balancing propensity score which models treatment assignment while
optimizing the covariate balance [23]. Third, following the method by Cao et
al. [14], one can explore alternative doubly robust estimators that can minimize the
asymptotic variance with correctly specified π(X, α) but misspecifiedmA(X, β),
and meanwhile apply restriction to drive estimated propensity scores away from
zero. Last but not least, instead of focusing on variance reduction, it may be
of interest to reduce bias following the bias-reduced doubly robust estimation by
Vermeulen and Vansteelandt [24].
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Appendix
Proof of Theorem 3. If the propensity score model π(X, α) is correctly specified,
we have
E [(a+ bA){m1(X, β)−m0(X, β)}] = E [E(a+ bA|X){m1(X, β)−m0(X, β)}]
= E [{a+ bπ(X)}{m1(X, β)−m0(X, β)}] ,
and
E
(
{a+ bπ(X)}
[
A
π(X)
{Y −m1(X, β)} −
1− A
1− π(X)
{Y −m0(X, β)}
])
= E
[
{a+ bπ(X)}
{
AY
π(X)
−
(1− A)Y
1− π(X)
}]
− E [{a+ bπ(X)}{m1(X, β)−m0(X, β)}] ,
= E [h(X){Y (1)− Y (0)}]−E [{a+ bπ(X)}{m1(X, β)−m0(X, β)}] ,
which implies τˆDRh → τh.
If the conditional mean modelmA(X, β) is correctly specified, we have
E
(
{a+ bπ(X, α)}
[
A
π(X, α)
{Y −m1(X)} −
1−A
1− π(X, α)
{Y −m0(X)}
])
= E
(
{a+ bπ(X, α)}E
[
A
π(X, α)
{Y (1)−m1(X)} −
1− A
1− π(X, α)
{Y (0)−m0(X)}
∣∣∣∣X
])
= E
(
{a+ bπ(X, α)}
[
π(X)
π(X, α)
E{Y (1)−m1(X)|X} −
1− π(X)
1− π(X, α)
E{Y (0)−m0(X)|X}
])
= 0,
and
E [(a + bA){m1(X)−m0(X)}] = E [{a+ π(X)}E{Y (1)− Y (0)|X}]
= E [h(X){Y (1)− Y (0)}] ,
which implies τˆDRh → τh. 
14
References
[1] Wang Y, Li L, Yang M, Liu H, Boden G, Yang G. Glucagon-like peptide-1
receptor agonists versus insulin in inadequately controlled patients with type
2 diabetes mellitus: a meta-analysis of clinical trials. Diabetes, Obesity and
Metabolism 2011; 13(11):972–981.
[2] Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity scores to
assess the generalizability of results from randomized trials. Journal of the
Royal Statistical Society: Series A (Statistics in Society) 2011; 174(2):369–
386.
[3] Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of random-
ized trial results to target populations. Prevention Science 2015; 16(3):475–
485.
[4] Pearl J, Bareinboim E. External validity: From do-calculus to transportabil-
ity across populations. Statistical Science 2014; 29(4):579–595.
[5] Hirano K, Imbens GW, Ridder G. Efficient estimation of average treat-
ment effects using the estimated propensity score. Econometrica 2003;
71(4):1161–1189.
[6] Vansteelandt S, Daniel RM. On regression adjustment for the propensity
score. Statistics in Medicine 2014; 33(23):4053–4072.
[7] Li F, Morgan LK, Zaslavsky AM. Balancing covariates via propensity score
weighting. 2014; ArXiv:1404.1785.
[8] Crump RV, Hotz J, Imbens I, Mitnik O. Moving the goalposts: addressing
limited overlap in the estimation of average treatment effects by changing
the estimand ; Technical Report No. 330, NBER Technical Working Paper
2006.
[9] Rosenbaum PR, Rubin DB. Constructing a control group using multivariate
matched sampling methods that incorporate the propensity score. The Amer-
ican Statistician 1985; 39(1):33–38.
[10] Rosenbaum PR. Optimal matching for observational studies. Journal of the
American Statistical Association 1989; 84(408):1024–1032.
15
[11] Hirano K, Imbens GW. Estimation of causal effects using propensity score
weighting: An application to data on right heart catheterization. Health Ser-
vices and Outcomes Research Methodology 2001; 2(3):259–278.
[12] Robins JM, Rotnitzky A, Zhao L. Estimation of regression coefficients when
some regressors are not always observed. Journal of the American Statistical
Association 1994; 89(427):846–866.
[13] Bang H, Robins JM. Doubly robust estimation in missing data and causal
inference models. Biometrics 2005; 61(4):962–973.
[14] Cao W, Tsiatis AA, Davidian M. Improving efficiency and robustness of
the doubly robust estimator for a population mean with incomplete data.
Biometrika 2009; 96(3):723–734.
[15] Tan Z. Bounded, efficient and doubly robust estimation with inverse weight-
ing. Biometrika 2010; 97(3):661–682.
[16] Rotnitzky A, Lei Q, Sued M, Robins JM. Improved double-robust estimation
in missing data and causal inference models. Biometrika 2012; 99(2):439–
456.
[17] Kaiser B. Decomposing differences in arithmetic means: a doubly robust
estimation approach. Empirical Economics 2016; 50(3):873–899.
[18] Robins J. A new approach to causal inference in mortality studies with a sus-
tained exposure period: application to control of the healthy worker survivor
effect. Mathematical Modelling 1986; 7(9):1393–1512.
[19] Murphy SA, van der Laan M, Robins JM. Marginal mean models for
dynamic regimes. Journal of the American Statistical Association 2001;
96(456):1410–1423.
[20] Robins JM, Herna´n MA. Estimation of the causal effects of time-varying ex-
posures. Longitudinal Data Analysis. Chapman and Hall/CRC Press: Boca
Raton, 2009; 553–599.
[21] Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA. In-
sulin vs glp-1 analogues in poorly controlled type 2 diabetic subjects on oral
therapy: a meta-analysis. Journal of Endocrinological Investigation 2013;
33(3):168–173.
16
[22] Han P, Wang L. Estimation with missing data: beyond double robustness.
Biometrika 2013; 100(2):417–430.
[23] Imai K, Ratkovic M. Covariate balancing propensity score. Journal of
the Royal Statistical Society: Series B (Statistical Methodology) 2014;
76(1):243–263.
[24] Vermeulen K, Vansteelandt S. Bias-reduced doubly robust estimation. Jour-
nal of the American Statistical Association 2015; 110(511):1024–1036.
17
Table 1: Simulation results for WATE τh under outcome model 1, based on 1000
Monte Carlo replications. π is the propensity score model andm is the conditional
mean model for the outcome. The marks of X and × indicate correct and incor-
rect model specifications, respectively. Bias is the average difference between the
estimate and the truth. RMSE is the square root of the average squared difference
between the estimate and the truth.
pi m Method
ATE ATT ATC ATO
Bias RMSE Bias RMSE Bias RMSE Bias RMSE
n = 200
-
X
τˆ
R
h
-
0.01
0.30 -
0.03
0.51 0.00 0.21 - -
× -
0.93
1.02 -
0.81
0.98 -
1.06
1.23 - -
X
- τˆI
h
-
0.07
0.42 -
0.03
0.56 -
0.13
0.54 -
0.01
0.28
× -
0.63
0.76 -
0.85
1.05 -
0.41
0.55 -
0.46
0.58
X X
τˆ
A
h
/ τˆDR
h
-
0.01
0.31 -
0.03
0.51 0.00 0.28 -
0.01
0.22
X × -
0.11
0.44 -
0.04
0.53 -
0.21
0.77 -
0.03
0.26
× X -
0.02
0.30 -
0.03
0.51 0.00 0.24 0.14 0.29
× × -
0.66
0.81 -
0.85
1.04 -
0.47
0.68 -
0.47
0.60
n = 1000
-
X
τˆ
R
h
0.00 0.16 0.00 0.30 0.00 0.09 - -
× -
0.92
0.94 -
0.80
0.87 -
1.04
1.08 - -
X
- τˆI
h
-
0.02
0.25 0.00 0.33 -
0.05
0.34 0.00 0.12
× -
0.62
0.66 -
0.84
0.90 -
0.41
0.44 -
0.45
0.49
X X
τˆ
A
h
/ τˆDR
h
0.00 0.17 0.00 0.30 0.00 0.13 0.00 0.09
X × -
0.03
0.27 0.00 0.30 -
0.06
0.47 -
0.01
0.10
× X 0.00 0.16 0.01 0.30 0.00 0.10 0.16 0.21
× × -
0.64
0.68 -
0.84
0.90 -
0.44
0.48 -
0.46
0.49
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Table 2: Simulation results for WATE τh under outcome model 2, based on 1000
Monte Carlo replications. π is the propensity score model andm is the conditional
mean model for the outcome. The marks of X and × indicate correct and incor-
rect model specifications, respectively. Bias is the average difference between the
estimate and the truth. RMSE is the square root of the average squared difference
between the estimate and the truth.
pi m Method
ATE ATT ATC ATO
Bias RMSE Bias RMSE Bias RMSE Bias RMSE
n = 200
-
X
τˆ
R
h
0.00 0.18 -
0.01
0.20 0.00 0.21 - -
× -
0.65
0.71 -
0.78
0.85 -
0.51
0.58 - -
X
- τˆI
h
-
0.05
0.36 0.00 0.32 -
0.11
0.55 -
0.01
0.24
× -
0.65
0.73 -
0.83
0.93 -
0.48
0.59 -
0.63
0.69
X X
τˆ
A
h
/ τˆDR
h
0.00 0.20 0.00 0.23 0.00 0.25 0.00 0.18
X × -
0.09
0.33 -
0.02
0.30 -
0.15
0.55 -
0.03
0.19
× X 0.00 0.19 -
0.01
0.21 0.00 0.22 0.01 0.18
× × -
0.66
0.73 -
0.83
0.92 -
0.49
0.58 -
0.63
0.69
n = 1000
-
X
τˆ
R
h
0.00 0.08 0.00 0.09 0.00 0.09 - -
× -
0.66
0.67 -
0.81
0.82 -
0.50
0.52 - -
X
- τˆI
h
-
0.02
0.22 -
0.01
0.15 -
0.04
0.36 -
0.01
0.08
× -
0.67
0.68 -
0.84
0.86 -
0.49
0.51 -
0.64
0.65
X X
τˆ
A
h
/ τˆDR
h
0.00 0.09 -
0.01
0.10 0.00 0.12 0.00 0.08
X × -
0.03
0.20 -
0.01
0.12 -
0.04
0.38 -
0.01
0.08
× X 0.00 0.08 0.00 0.09 0.00 0.09 0.02 0.08
× × -
0.67
0.68 -
0.84
0.86 -
0.49
0.51 -
0.64
0.65
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Table 3: Weightedmean (SE) differences in HbA1c (%) reduction after six months
of GLP-1 RA vs. insulin therapies among patients with type 2 diabetes, with
positive numbers favoring insulin. The ATT is for the patient population on GLP-
1 RA while the ATC is for the patient population on insulin.
Method ATE ATT ATC ATO
Unweighted 1.06 (0.20) - - -
τˆ
R
h
0.34 (0.36) 0.25 (0.36) 0.38 (0.46) -
τˆ
I
h
0.44 (0.45) 0.12 (0.57) 0.54 (0.69) 0.37 (0.29)
τˆ
A
h
/ τˆDR
h
0.13 (0.43) -0.02 (0.61) 0.19 (0.53) 0.27 (0.31)
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